Before the drug enters the clinical phase trial, it is necessary to evaluate the biological activity and pharmacokinetic information of the drug through various technologies and methods. Since it was difficult to obtain a large number of human diseased functional cells in the past, especially the functional cells in the early stage of the disease, traditional pre-clinical tests to detect drug toxicity often need to rely on experimental animal models, cancer cell lines or a small number of human primary cells. However, in many cases, the physiological conditions of these experimental models and the actual human body are very different, which directly leads to the high failure rate of new drug development in the clinical trial phase, and will greatly greatly enhance the R & D cost.

At present, Nuwacell Biotechnologies Co., Ltd. has been able to prepare large quantities of stable disease-specific and healthy control human induced pluripotent stem cells (iPSC), including Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) and other related diseases. Researchers can use the differentiated functional cells derived from these disease-specific iPSC to conduct disease-related candidate drugs screening, including effectiveness and dosage ranges.